瑞舒伐他汀对颈动脉粥样硬化患者单个核细胞CCR2表达的影响及机制

doi:10.13459/j.cnki.cjap.2016.03.003

中国应用生理学杂志 ›› 2016, Vol. 32 ›› Issue (3): 202-206.doi: 10.13459/j.cnki.cjap.2016.03.003

瑞舒伐他汀对颈动脉粥样硬化患者单个核细胞CCR2表达的影响及机制

杜瑞雪¹, 叶平¹, 颜光涛², 邓子辉², 梁文涛³, 郭子宽⁵, 张红红⁴, 耿淼⁴

1. 解放军总医院南楼心内科, 北京 100853;
2. 解放军总医院基础医学研究所, 北京 100853;
3. 解放军总医院普通外科研究所, 北京 100853;
4. 解放军总医院老年医学研究所, 北京 100853;
5. 军事医学科学院放射与免疫研究所, 北京 100850

收稿日期:2016-01-22 修回日期:2016-03-07 出版日期:2016-05-28 发布日期:2018-06-12
通讯作者: 叶平,Tel:010-66876369;E-mail:yeping301@sina.com E-mail:yeping301@sina.com
基金资助:
国家自然科学基金项目（81270941）

The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway

DU Rui-xue¹, YE Ping¹, YAN Guang-tao², DENG Zi-hui², LIANG Wen-tao³, GUO Zi-kuan⁵, ZHANG Hong-hong⁴, GEN Miao⁴

1. Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing 100853;
2. Institue of Basic Medical Sciences, Chinese PLA General Hospital, Beijing 100853;
3. Institute of Surgery, Chinese PLA General Hospital, Beijing 100853;
4. Institute of Geriatrics, Chinese PLA General Hospital, Beijing 100853;
5. Radiology and Immunology Institute, Academy of Military Medical Sciences, Beijing 100850, China

Received:2016-01-22 Revised:2016-03-07 Online:2016-05-28 Published:2018-06-12
Supported by:
国家自然科学基金项目（81270941）

摘要/Abstract

摘要： 目的：探讨瑞舒伐他汀对颈动脉粥样硬化患者单个核细胞CC类趋化因子受体2（CCR2）表达的影响及上游机制。方法：选择颈动脉粥样硬化患者20例。予瑞舒伐他汀5~20 mg/d治疗。在基线、3月时采集血标本，测定单核细胞趋化蛋白-1（MCP-1）及血脂水平；分离单个核细胞，流式细胞学检测单个核细胞上的CCR2表达；荧光定量逆转录PCR法检测CCR2、过氧化物酶体增生物激活受体（PPAR）β mRNA的表达；Western印迹法检测PPAR β蛋白的表达。结果：瑞舒伐他汀治疗3个月后，患者低密度脂蛋白胆固醇（LDL-C）水平明显降低（P<0.01），MCP-1及单个核细胞CCR2表达显著下降（P<0.05），PPAR β mRNA及蛋白表达均较前增加（P<0.05）。结论：瑞舒伐他汀可能通过PPAR β途径降低MCP-1，抑制单个核细胞CCR2的表达。

关键词: 瑞舒伐他汀, 动脉粥样硬化, CC类趋化因子受体2, 过氧化物酶体增生物激活受体β

Abstract: Objective:To investigate the effect of rosuvastatin therapy on C-C chemokine receptor(CCR2)expression in mononuclear cells in patients with carotid atherosclerosis and explore the possible upstream mechanism. Methods:Twenty patients without previous statin treatment were enrolled. Rosuvastatin were given 5 to 20 mg/day for 3 months. At baseline and 12 weeks, lipid profile and plasma monocyte chemotactic protein-1 (MCP-1) levels were examined. The mRNA and protein expressions of CCR2 in the mononuclear cells were measured with RT-PCR and flow cytometry, respectively. The mRNA and protein expression of peroxidase proliferator-activated receptor(PPAR β) were detected with RT-PCR and Western blot, respectively. Results:After 3-months rosuvastatin treatment, the patients' low-density lipoprotein cholesterol (LDL-C) levels decreased significantly (P<0.01). Compared with baseline, the mRNA and protein expressions of CCR2 in the mononuclear cells showed significantly decrease, as well as plasma MCP-1 levels (P<0.05). Both mRNA and protein expressions of PPAR β in the mononuclear cells increased (P<0.05). Conclusion:Rosuvastatin may attenuate MCP-1/CCR2 through PPARβ upstream pathway.

Key words: rosuvastatin, atherosclerosis, CCR2, PPAR β

杜瑞雪, 叶平, 颜光涛, 邓子辉, 梁文涛, 郭子宽, 张红红, 耿淼. 瑞舒伐他汀对颈动脉粥样硬化患者单个核细胞CCR2表达的影响及机制[J]. 中国应用生理学杂志, 2016, 32(3): 202-206.

DU Rui-xue, YE Ping, YAN Guang-tao, DENG Zi-hui, LIANG Wen-tao, GUO Zi-kuan, ZHANG Hong-hong, GEN Miao. The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway[J]. CJAP, 2016, 32(3): 202-206.

参考文献

[1] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins[J]. Lancet, 2005, 366(9493):1267-1278.
[2] 赵佳慧, 程庆砾, 叶平. 阿托伐他汀治疗对肾脏衰老的影响[J]. 中国应用生理学杂志, 2011, 27(1):98-101.
[3] 韩磊, 叶平, 李鸣皋. PPARα信号通路在阿托伐他汀抑制衰老心肌MMP-9表达中的作用[J]. 中国应用生理学杂志, 2013, 29(5):469-472.
[4] Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy:an analysis from the JUPITER trial[J]. Lancet, 2010, 376(9738):333-339.
[5] Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro[J]. Eur J Harmacol, 2000, 410(1):83-92.
[6] Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-γand attenuates the inflammatory response in human monocytes[J]. Inflamm Res, 2002, 51(2):58-62.
[7] Olzinski AR, Turner GH, Bernard RE, et al. Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/-mouse:magnetic resonance imaging assessment[J]. Arterioscler Thromb Vasc Biol, 2010, 30(2):253-259.
[8] Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets[J]. Immunobiol, 2006, 211(6-8):609-618.
[9] Izikson L, Klein RS, Charo IF, et al. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2[J]. J Exp Med, 2000, 192(7):1075-1080.
[10] Brodmerkel CM, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodentactive CCR2 antagonist, INCB3344[J]. J Immunol, 2005, 175(8):5370-5378.
[11] Han KH, Ryu J, Hong KH, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo[J]. Circulation, 2005, 111(11):1439-1447.
[12] Yuichi M, Daisuke O, Jun W, et al. Activation of peroxisome proliferator-activated receptord inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice[J]. Diabetes, 2011, 60(3):960-968.
[13] Fan Y, Wang Y, Tang Z, et al. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells[J]. Arterioscler Thromb Vasc Biol, 2008, 28(2):315-321.
[14] Barish GD, Atkins AR, Downes M, et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis[J]. Proc Natl Acad Sci USA, 2008, 105(11):4271-4276.
[15] Schnegg CI, Kooshki M, Hsu FC, et al. PPARδ prevents radiation-induced proinflammatory responses in microglia via transrepression of NF-κB and inhibition of the PKCα/MEK1/2/ERK1/2/AP-1 pathway[J]. Free Radical Biol Med, 2012, 52(9):1734-1743.
[16] Liu G, Li X, Li Y, et al. PPARε agonist GW501516 inhibits pdgf-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling[J]. Biomed Res Int, 2013, 2013:903947.
[17] Lazar A, Bojic, Amy C, et al. Peroxisome proliferator-activated receptorδagonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice[J]. Arterioscler Thromb Vasc Biol, 2014, 34(1):52-60.
[18] Inoue I, Itoh F, Aoyagi S, et al. Fibrate and statin synergistically increase the transcriptional activities of PPARa/RXRa and decrease the transactivation of NF-kB[J]. Biochem Biophys Res Commun, 2002, 290(1):131-139.

瑞舒伐他汀对颈动脉粥样硬化患者单个核细胞CCR2表达的影响及机制

The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	汪晨净, 裴淑燕, 南晓东, 马艳庆. 内皮素-1对大鼠血管平滑肌细胞产生MCP-1的影响及其机制[J]. 中国应用生理学杂志, 2018, 34(3): 283-288.
[2]	周昌钻, 潘孙雷, 林辉, 孟立平, 季政, 池菊芳, 郭航远. 瑞舒伐他汀对同型半胱氨酸诱导的小鼠血管平滑肌细胞去分化和内质网应激的影响及其机制研究[J]. 中国应用生理学杂志, 2018, 34(1): 43-48.
[3]	王敏, 刘善云, 张洪侠, 王亚慧, 刘凯. 耐力训练对ApoE^-/-致AS小鼠IL-18和IL-10表达的影响[J]. 中国应用生理学杂志, 2016, 32(3): 225-228.